Sarah Cannon Research Institute to Present Latest Oncology Research Insights at 2023 ASCO® Annual Meeting

More Than 135 Abstracts Accepted for Presentation Across All Phases of Drug Development

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023. More than 80 experts from SCRI’s research network participated in key research that will be presented at the Annual Meeting, including important updates for 64 early-phase studies as well as a number of late-phase trials for multiple types of cancer, including breast, lung, hematologic malignancies, and more.

In 2022, SCRI joined together with US Oncology Research as one company to transform oncology research and improve care in more than 24 states across the U.S. Operating as SCRI, the unified research network has over 1,300 physicians enrolling patients to more than 1,000 trials annually.

“The collaborations across SCRI’s expanded network are accelerating progress and serving more patients closer to where they live,” says Howard A. “Skip” Burris III, MD, President, SCRI. “We are looking forward to this year’s Annual Meeting where we will be discussing the results of trials that are advancing therapies across a variety of cancers.”

For a comprehensive list of abstracts and presentations, click here.

Noteworthy Presentations:

Breast Cancer:

• Erika Hamilton, MD, SCRI at Tennessee Oncology, will give two oral presentations – “Efficacy and Safety Results by Age in monarchE: Adjuvant Abemaciclib Combined with Endocrine Therapy in Patients with HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer” on June 2 at 2:45 p.m. CDT in Hall D1 and “A Phase 2 Study of HER3-DXd in Patients with Metastatic Breast Cancer” on June 5 at 11:30 a.m. CDT in Hall B1.
• Denise Yardley, MD, SCRI at Tennessee Oncology, contributed to research featured in the oral presentation, “Ribociclib and Endocrine Therapy as Adjuvant Treatment in Patients with HR+/HER2− Early Breast Cancer: Primary Results from the Phase III NATALEE Trial,” which will take place on June 2 at 2:45 p.m. CDT in Hall D1.

Genitourinary Cancer:

• Thomas Hutson, DO, PharmD, SCRI at Texas Oncology I The US Oncology Network, will deliver “Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-Up of Lenvatinib Plus Pembrolizumab vs Sunitinib in Patients with Advanced Renal Cell Carcinoma” in an oral presentation on June 5 at 11:30 a.m. CDT in Hall D1.

Lung Cancer:

• Melissa Johnson, MD, SCRI at Tennessee Oncology, will present “ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab Etrumadenant vs Zimberelimab in First-Line, Metastatic, PD-L1-High Non-Small Cell Lung Cancer” in the ASCO Plenary Series: Rapid Abstract Updates on June 3 at 12:30 p.m. CDT in the Arie Crown Theater. Dr. Johnson also co-authored research that will be featured in the oral presentation, “First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6 –Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer,” on June 5 at 8 a.m. CDT in Hall D2.

Melanoma/Skin Cancer:

• Meredith McKean, MD, MPH, SCRI at Tennessee Oncology, participated in research that will be featured in the oral presentation, “Distant Metastasis-Free Survival Results from the Randomized, Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial,” on June 5 at 3 p.m. CDT in Hall D1.

In addition to the scientific presentations, SCRI leadership will participate in and lead ASCO sessions, including:

• Dr. McKean will chair the education session, New Drugs in Oncology: Incorporation into Practice, on June 2 at 2:45 p.m. CDT in E450.
• Benjamin Garmezy, MD, SCRI at Tennessee Oncology, will discuss “The Power of Patients’ Experiences to Inform Therapeutic Decisions” in the poster discussion session, Genitourinary Cancer—Kidney and Bladder, on June 3 at 3 p.m. CDT in E450.
• Dr. Hamilton will chair the Highlights of the Day session on June 4 at 8:15 a.m. CDT in Hall D1 and present “The Next Frontier: Resistance to ADCs and Combination Strategies” in the education session, Next-Generation Antibody-Drug Conjugates: Past, Present, and Future, on June 4 at 4:30 p.m. CDT in Hall D2.
• Cesar Perez, MD, SCRI at Florida Cancer Specialists, will chair the Head and Neck Cancer oral abstract session on June 5 at 8 a.m. CDT in Hall B1.
• Manojkumar Bupathi, MD, MS, SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, will chair the oral abstract session, Genitourinary Cancer – Kidney and Bladder, on June 5 at 11:30 a.m. CDT in E450.

Additional Poster Presentations with SCRI First Authors:

Saturday, June 3, 2023

• “Phase 1/1b Study of SY-5609, a Selective and Potent CDK7 Inhibitor, in Advanced Solid Tumors and in 2L/3L Pancreatic Ductal Adenocarcinoma in Combination with Gemcitabine +/- Nab-Paclitaxel,” Babar Bashir, MD, SCRI at Sidney Kimmel Cancer Center, 8 a.m. CDT, Hall A
• “First-in-Human Phase 1 Study of Pimicotinib, a CSF-1R Inhibitor, in Patients with Advanced Solid Tumors,” Gerald Falchook, MD, MS, SCRI at HealthONE, 8 a.m. CDT, Hall A
• “Safety and Efficacy of DB-1303 in Patients with Advanced/Metastatic Solid Tumors: A Multicenter, Open-Label, First-in-Human, Phase 1/2a Study,” Kathleen Moore, MD, MS, SCRI at Stephenson Cancer Center, 8 a.m. CDT, Hall A
• “BLU-222, an Oral, Potent and Selective CDK2 Inhibitor, in Patients with Advanced Solid Tumors: Phase 1 Monotherapy Dose Escalation,” Manish Patel, MD, SCRI at Florida Cancer Specialists, 8 a.m. CDT, Hall A
• “MyTACTIC: Efficacy and Safety of Atezolizumab + Chemotherapy in Patients with Advanced Unresectable/Metastatic Solid Tumors with High Tumor Mutational Burden or High Microsatellite Instability/Deficient Mismatch Repair,” David Spigel, MD, SCRI at Tennessee Oncology, 8 a.m. CDT, Hall A
• “A Phase 1 Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors,” Susanna Ulahannan, MD, MMed, SCRI at Stephenson Cancer Center, 8 a.m. CDT, Hall A
• “A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of cln-619 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors,” Judy Wang, MD, SCRI at Florida Cancer Specialists, 8 a.m. CDT, Hall A

Sunday, June 4, 2023

• “Management of Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer Who Received Brain Radiotherapy on Study in the Phase 3 CROWN Trial,” Todd Bauer, MD, SCRI at Tennessee Oncology, 8 a.m. CDT, Hall A

Monday, June 5, 2023

• “Correlating Expression of NaPi2b and FRa in High Grade Serous Ovarian Cancer,” Debra Richardson, MD, FACS, FACOG, SCRI at Stephenson Cancer Center, 1:15 p.m. CDT, Hall A
• “Preliminary Results from ERAS-007 Plus Palbociclib in Patients with KRAS/NRAS Mutant Colorectal Cancer or KRASm Pancreatic Ductal Adenocarcinoma in HERKULES-3 Study: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Pts with Advanced Gastrointestinal Malignancies,” Susanna Ulahannan, MD, MMed, SCRI at Stephenson Cancer Center, 8 a.m. CDT, Hall A

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the U.S. Learn more about our research offerings.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230601005464/en/